中
繁
EN
Search form
Search this site
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Platform & Pipeline
Platform
Pipeline
SHP2
KRAS G12C
BET
Aurora A
CD73
Partnership
News
Company News
Media Report
For patients
找到
13
个临床实验
All
Advanced solid tumors
Advanced tumors
Advanced CRC
NSCLC
Esophageal Cancer
分子：
JAB-3068
条件：
Advanced solid tumors
链接：
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
分子：
JAB-3068
条件：
Advanced solid tumors
链接：
A Phase 1/2a, Multi-Center, Dose Escalation/Dose Expansion, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
分子：
JAB-3068
条件：
Advanced solid tumors
链接：
A Phase 1b/2a, Multi-Center, Open-Label，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JAB-3068 in Combination With JS001 in Patients With Advanced Solid Tumors
分子：
JAB-3312
条件：
Advanced solid tumors
链接：
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
分子：
JAB-3312
条件：
Advanced solid tumors
链接：
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors
分子：
JAB-3312
条件：
Advanced solid tumors
链接：
A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors
分子：
JAB-8263
条件：
Advanced tumors
链接：
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
分子：
JAB-8263
条件：
Advanced tumors
链接：
A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors
分子：
JAB-21822
条件：
Advanced solid tumors
链接：
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
分子：
JAB-21822
条件：
Advanced solid tumors
链接：
Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12c Mutations
分子：
JAB-21822
条件：
NSCLC
链接：
A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
分子：
JAB-21822
条件：
Advanced CRC
链接：
A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
分子：
JAB-BX102
条件：
Advanced solid tumors
链接：
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
京公网安备 11030102011242号